Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
Bhasin RCT: 12wk testosterone after RP raised sexual activity by 0.91 daily events vs placebo (95% CI 0.56-1.26, P<.001), with zero biochemical recurrences in either arm.
The day's only readout is in prostate. A randomized phase 2 of TRT in hypogonadal men with low-grade disease and undetectable PSA after RP met its sexual-activity endpoint with no BCR. The 12wk exposure is too short to establish oncologic safety, and ADT- or RT-treated men were excluded, so this does not transfer to post-RT survivors.
read the full digest →Studies · 132
- TRT in Prostate Cancer Survivors (Bhasin RCT)Sexual activity +0.91 daily events vs placebo (95% CI 0.56-1.26, P<.001) with 12wk testosterone; zero biochemical recurrences in low-grade post-RP hypogonadal men.
- ASTRO Clinical Practice Guideline: RT for Bladder CancerTMT recommended (strong, high QoE) as alternative to RC for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
- Gamma Knife vs LINAC-based radiosurgery for vestibular schwannoma (retrospective review)Local control 98.8%; no difference in new vertigo, gait disturbance or facial palsy with GKRS (n=36) vs LINAC (n=49) SRS for vestibular schwannoma.
- SWOG S1827/MAVERICKRandomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.
- TORPEdO18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
- Testosterone recovery post-ADT discontinuation (podcast review)Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
- Moderately hypofractionated partial breast reirradiation40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).